



Figure.S1


A. LTB-Ss



B. LTB



C. LTB-Ss (Post-Treatment)



**Figure S1. LTB-Ss, LTB and LTB-Ss post treatment individuals exhibit significantly increased production of Type 1, 17, 2 and regulatory cytokines upon mycobacterial - antigen stimulation** (A) The baseline and mycobacterial antigen - stimulated levels of Type 1 (IFN  $\gamma$ , TNF  $\alpha$ , IL-2) Type 17 (IL-17A, IL-17F, IL-22) Type 2 (IL-4, IL-5, IL-13) and regulatory (IL-10, TGF  $\beta$ ) cytokines were measured in LTB-Ss individuals (n=60). (B) Mycobacterial antigen - stimulated levels of Type 1 (IFN  $\gamma$ , TNF  $\alpha$ , IL-2) Type 17 (IL-17A, IL-17F, IL-22) Type 2 (IL-4, IL-5, IL-13) and regulatory (IL-10, TGF  $\beta$ ) cytokines were measured in LTB individuals (n=58). (C) The post-treatment and mycobacterial antigen - stimulated levels of Type 1 (IFN  $\gamma$ , TNF  $\alpha$ , IL-2) Type 17 (IL-17A, IL-17F, IL-22) Type 2 (IL-4, IL-5, IL-13) and regulatory (IL-10, TGF  $\beta$ ) cytokines were measured in LTB-Ss individuals (n=60).